Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

75.0%

3 terminated/withdrawn out of 4 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
1(25.0%)
Early Phase 1
1(25.0%)
4Total
Phase 1(2)
Phase 2(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05395260Early Phase 1Withdrawn

FL- 101 Study in Non-Metastatic MIBC

Role: lead

NCT04983732Phase 1Completed

A Bioavailability Study of FL-101 in Healthy Male and Female Subjects

Role: lead

NCT05181865Phase 1Withdrawn

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Role: lead

NCT04758949Phase 2Withdrawn

FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

Role: lead

All 4 trials loaded